Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions
Psychiatria · 2025
DOI: 10.5603/psych.106162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatria, 2025. Verfasst von Michał Pałuchowski und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
This article provides an overview of emerging pharmacotherapeutic approaches to support the management of symptoms in patients suffering from borderline personality disorder (BPD). Aim of review: BPD is a complex and severe mental disorder characterized by a pervasive pattern of emotional dysregulation, marked impulsivity, instability in interpersonal relationships, a distorted sense of self, and an increased risk of suicide. It represents a significant public health problem due to its relatively high prevalence, associated morbidity, and substantial economic burden. Despite that, there is currently no medication approved by the European Medicines Agency (EMA) or the Food and Drug Administration (FDA) specifically for BPD.
Conclusions
Pharmacological agents such as omega-3 fatty acids, opioid antagonists, clonidine, ketamine or esketamine, memantine, and oxytocin demonstrate preliminary potential in targeting specific dimensions of BPD pathology. Omega-3 fatty acids may reduce impulsivity and affective instability, opioid antagonists may help reduce self-harm and impulsivity, clonidine may lower hyperarousal, ketamine and esketamine are being investigated for rapid relief from suicidal ideation and improvement in social functioning, primarily in the context of comorbid depression, and oxytocin may modulate stress responses and enhance social engagement. However, further research, particularly through well-designed, large-scale clinical trials is necessary to confirm their efficacy, assess optimal intervention parameters, and establish their role in clinical practice. The successful integration of these emerging adjunctive approaches into clinical practice has the potential to significantly improve outcomes for individuals with BPD and enhance the overall management of this debilitating disorder.
Zitieren
APA
Pałuchowski, M., Krawczyk, A., Mozer, M., Możarowski, W., Pietruszka, W., Krupa, A., Potrykus, M., Klasicki, P., Mateńko, J., Kiełbratowska, J., & Kwiecińska, J. (2025). Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions. Psychiatria. https://doi.org/10.5603/psych.106162
Vancouver
Pałuchowski M, Krawczyk A, Mozer M, Możarowski W, Pietruszka W, Krupa A, et al. Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions. Psychiatria. 2025. doi:10.5603/psych.106162
BibTeX
@article{Pauchowski2025,
author = {Pałuchowski, Michał and Krawczyk, Anna and Mozer, Maciej and Możarowski, Wiktor and Pietruszka, Wiktoria and Krupa, Agata and Potrykus, Maria and Klasicki, Przemysław and Mateńko, Jan and Kiełbratowska, Julia and Kwiecińska, Julia},
title = {Emerging pharmacological strategies supporting symptom management in borderline personality disorder: current evidence and future directions},
journal = {Psychiatria},
year = {2025},
doi = {10.5603/psych.106162}
}
EUVIMED